Rigaku Analytical Devices Inc, 30 Upton Dr, # 2, Wilmington, MA 01887, US

Aquilus Pharmaceuticals Inc is a privately held biotechnology company based in Woburn, MA, specializing in the treatment and management of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. They have developed a promising MMP-2 and MMP-9 inhibitor, AQU-118, which has shown efficacy in reducing neuronal damage in animal models of nerve injury. Aquilus believes that ALS is a result of a systemic wide inflammatory process triggered by mis-folding events, leading to the overexpression and production of MMP-9 in motor neurons. Their research suggests that the uncontrollable rise in MMP-9 levels contributes to the breakdown of vital CNS proteins and the activation of inflammatory cytokines, ultimately leading to motor neuron cell death. Aquilus aims to complete all necessary studies by the end of 2022 and begin clinical development of AQU-118 for ALS treatment in 2023.Generated from the website

Toshiba Business Solutions

FedEx Drop Box

North Atlantic Networks

Polychromix